Project Grant R15AT014052
Award Date 8/17/26
Completion Date 7/31/29
Dollars Obligated $560K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Teaneck, NJ 07666, USA
Similar Awards
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of North Carolina at Chapel Hill a $222,758 Project Grant on August 7, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research through July 31, 2027. The award funds a comprehensive neuroscience investigation aimed at delineating how different molecularly defined dorsal root ganglia (DRG) neuron types contribute to pain representation...
- The National Institute of Neurological Disorders and Stroke awarded Rutgers, The State University $118,593 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853, Assistance Listing). The award funds research investigating the role of dorsal horn interneurons expressing the serotonin 6 receptor (5HTR6+ interneurons) in sensorimotor integration within the spinal cord under both normal conditions and following spinal cord...
- The National Institute of Neurological Disorders and Stroke awarded Rutgers The State University of New Jersey (RBHS-School of Nursing) $787,111 on September 5, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate a humanized antisense oligonucleotide (ASO) targeting nerve injury-specific long non-coding RNA (NIS) as a non-opioid, non-addictive analgesic for chronic neuropathic pain. The R61 phase includes design, synthesis, and purification of...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Lowell $2.272 million on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to discover novel, non-opioid, non-addictive analgesics derived from marine microbial natural products. The award funds a phenotypic screening effort combining human induced pluripotent stem cell sensory neurons and glia cultured on multi-well microelectrode arrays to characterize sensory neuron...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $713,227 to the University of Wisconsin–Madison on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Project Grant R01DK146259). The award funds research on the role of A-fiber mechanosensitive neurons in bladder function and urologic disease phenotypes, with focus on urologic chronic pelvic pain syndrome (UCPPS). The research team has developed new tools for...
- The National Institute on Drug Abuse awarded the University of Utah $162,200 on October 10, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to characterize pain embodiment and its relationship to opioid misuse risk in chronic pain using neuroimaging. The award funds a five-year research project through September 30, 2030, performed in Salt Lake City, Utah. The research will employ resting-state functional magnetic resonance imaging to study pain embodiment—the tendency...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.119 million on September 18, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate computational and clinical tools for understanding pain variability in sickle cell disease. The funded work constitutes a prospective cohort study enrolling 1,250 individuals aged 15 years and older living with sickle cell disease in the United States. Over three years, the research...
- The National Institute of Neurological Disorders and Stroke awarded The Ohio State University $10.115 million on September 12, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a prospective observational study modeling diverse experiences and longitudinal trajectories of acute pain in emergency department settings. The study—titled MODEL-PAIN (MOdeling Diverse Experiences and Longitudinal trajectories of pain)—will enroll 2,400 emergency department patients and...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $407,113 to the University of California, Irvine on August 15, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support development of novel KV7 channel modulators for pain therapy. This R21 exploratory research grant, which concludes July 31, 2027, will establish an empirical foundation for developing therapies targeting...